

.....  
(Original Signature of Member)

117TH CONGRESS  
1ST SESSION

**H. R.** \_\_\_\_\_

To direct the Secretary of Health and Human Services and other Federal officials to compile into a searchable database information relating to Federal support for biomedical research and development related to COVID–19, and for other purposes.

---

IN THE HOUSE OF REPRESENTATIVES

Mr. DOGGETT introduced the following bill; which was referred to the Committee on \_\_\_\_\_

---

**A BILL**

To direct the Secretary of Health and Human Services and other Federal officials to compile into a searchable database information relating to Federal support for biomedical research and development related to COVID–19, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Taxpayer Research  
5 and Coronavirus Knowledge Act of 2021”.

1 **SEC. 2. DATABASE.**

2 (a) IN GENERAL.—The Secretary of Health and  
3 Human Services, the Director of the National Institutes  
4 of Health, the Assistant Secretary for Preparedness and  
5 Response of the Department of Health and Human Serv-  
6 ices, the Director of the Biomedical Advanced Research  
7 and Development Authority, the Secretary of Defense, the  
8 Secretary of Veterans Affairs, the Director of the National  
9 Institute of Allergy and Infectious Diseases, and such  
10 other Federal officials as the Secretary of Health and  
11 Human Services determines to be relevant, acting in co-  
12 ordination, shall—

13 (1) compile into a searchable database informa-  
14 tion relating to Federal support (before or after the  
15 date of enactment of this Act) for biomedical re-  
16 search and development related to COVID–19 (in-  
17 cluding biomedical research and development relat-  
18 ing to a product or therapy that was later modified  
19 or repurposed to be used for COVID–19); and

20 (2) make such database available on the public  
21 website of the Department of Health and Human  
22 Services.

23 (b) COVERED INFORMATION.—The information relat-  
24 ing to Federal support referred to in subsection (a)(1) in-  
25 cludes all contracts, funding agreements, licensing ar-  
26 rangements, other transactions, and other arrangements

1 entered into by or on behalf of the Federal Government  
2 and tax benefits provided with respect to research and de-  
3 velopment, and manufacturing, of a drug (including a bio-  
4 logical product), cell or gene therapy, or medical device  
5 intended to be manufactured, used, designed, developed,  
6 modified, repurposed, licensed, or procured to diagnose,  
7 mitigate, prevent, treat, or cure COVID–19, including the  
8 following:

9           (1) Licensing agreements pursuant to section  
10       207 or 209 of title 35, United States Code.

11           (2) Cooperative research and development  
12       agreements and licensing agreements pursuant to  
13       section 3710a of title 15, United States Code.

14           (3) Funding agreements, as defined under sec-  
15       tion 201 of title 35, United States Code.

16           (4) Transactions, contracts, grants, cooperative  
17       agreements, other agreements, and other arrange-  
18       ments entered into pursuant to the following stat-  
19       utes:

20                   (A) The Public Health Service Act (42  
21       U.S.C. 201 et seq.), including sections 301,  
22       319L, 421, and 480 of such Act (42 U.S.C.  
23       241, 247d–7e, 285b–3, 287a).

1 (B) Section 105 of the National Institutes  
2 of Health Reform Act of 2006 (42 U.S.C.  
3 284n).

4 (C) Chapter 139 of title 10, United States  
5 Code (10 U.S.C. 2351 et seq.), including sec-  
6 tions 2358, 2371, 2371a, 2371b, and 2373.

7 (5) Grants, contracts, and other transactions  
8 pursuant to section 2371, 2371a, or 2371b of title  
9 10, United States Code.

10 (6) Procurement contracts and other agree-  
11 ments pursuant to section 2373 of title 10, United  
12 States Code.

13 (c) INFORMATION REQUIRED.—Notwithstanding any  
14 other provision of law, the Federal officials referred to in  
15 subsection (a) shall include in the database under sub-  
16 section (a), with regard to each contract, funding agree-  
17 ment, licensing agreement, other transaction, other ar-  
18 rangement, or tax benefit described in subsection (b), at  
19 least the following information:

20 (1) The agency, program, institute, or other  
21 Federal Government entity providing the Federal  
22 grant, cooperative agreement, or other support.

23 (2) The amount and period of Federal financial  
24 support with an itemized breakdown.

1           (3) Other Federal nonfinancial support, includ-  
2           ing the use of Federal personnel, Federal facilities,  
3           and Federal equipment.

4           (4) The grant number, if applicable.

5           (5) Associated clinical trial data, upon trial  
6           completion.

7           (6) Associated patents and patent applications,  
8           specifying—

9                   (A) any Federal ownership in such patents  
10                   and patent applications;

11                   (B) the expiration date of such patents  
12                   and filing dates of such patent applications; and

13                   (C) the numbers of such patents and pat-  
14                   ent applications.

15           (7) Associated periods of marketing exclusivity  
16           under Federal law and the durations of such peri-  
17           ods.

18           (8) The corporation, nonprofit organization,  
19           academic institution, person, or other entity receiv-  
20           ing the Federal support.

21           (9) Any products (including repurposed prod-  
22           ucts) approved, authorized, or cleared for marketing,  
23           or for which marketing approval, authorization, or  
24           clearance is being sought, the development of which  
25           was aided by Federal support, including—

- 1 (A) the names of such products;  
2 (B) the prices of such products; and  
3 (C) the current and anticipated manufac-  
4 turing capacity to produce such products.

5 (10) The full terms of the contract, funding  
6 agreement, licensing agreement, other transaction,  
7 or other arrangement described in subsection (b).

8 (d) **FORMAT OF INFORMATION.**—The database under  
9 subsection (a) shall be—

10 (1) searchable and filterable according to the  
11 categories of information described in subsection (c);  
12 and

13 (2) presented in a user-friendly format.

14 (e) **TIMING.**—The database under subsection (a)  
15 shall be—

16 (1) made publicly available not later than 1  
17 month of the date of enactment of this Act; and

18 (2) updated not less than every 2 weeks.

19 (f) **DISCLOSURE.**—

20 (1) **IN GENERAL.**—Notwithstanding any other  
21 provision of law, to the extent necessary for an offi-  
22 cial referred to in subsection (a) to carry out this  
23 section, such official may require entities receiving  
24 Federal support referred to in subsection (a)(1) to  
25 disclose to the official any information relating to

1       such Federal support and required to be included in  
2       the database under subsection (a).

3           (2) INTERMEDIARY COOPERATION.—Any ar-  
4       rangement entered into by the Federal Government  
5       with an entity providing for such entity to enter into  
6       contracts, licensing agreements, grants, other trans-  
7       actions, or other arrangements with third parties on  
8       behalf of the Federal Government shall require such  
9       entity to disclose in a timely manner any informa-  
10      tion necessary for the Federal Government to fulfill  
11      its duties under this Act. With respect to any such  
12      arrangement in place as of the date of enactment of  
13      this Act, an official referred to in subsection (a) may  
14      require the entity to disclose to the official any infor-  
15      mation required to be included in the database  
16      under subsection (a).

17           (3) PENALTY FOR NONDISCLOSURE.—If an en-  
18      tity that is required to disclose information pursuant  
19      to paragraph (1) or (2) fails to disclose such infor-  
20      mation by the date that is two weeks after the date  
21      on which the official requests such information, or  
22      by such reasonable deadline as the official may  
23      specify, whichever is sooner, then such entity shall  
24      be liable to the United States for a civil penalty in

- 1 an amount not to exceed \$10,000 for each day on
- 2 which such failure continues.